Therese Vallerskog

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE
    Therese Vallerskog
    Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden
    Clin Immunol 122:62-74. 2007
  2. ncbi Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
    Therese Vallerskog
    Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, CMM L8 04, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Arthritis Res Ther 8:R167. 2006
  3. ncbi Serial re-challenge with influenza vaccine as a tool to study individual immune responses
    Therese Vallerskog
    Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
    J Immunol Methods 339:165-74. 2008
  4. ncbi HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay
    Heidi Wähämaa
    Rheumatology Unit, Department of Medicine, Karolinska Institutet CMM L8 04, Karolinska sjukhuset, Stockholm, Sweden
    J Leukoc Biol 81:129-36. 2007

Collaborators

Detail Information

Publications4

  1. ncbi Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE
    Therese Vallerskog
    Rheumatology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Sweden
    Clin Immunol 122:62-74. 2007
    ..In conclusion, both the humoral and the cellular immune systems were affected by treatment with rituximab...
  2. ncbi Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis
    Therese Vallerskog
    Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, CMM L8 04, Karolinska Hospital, SE 171 76 Stockholm, Sweden
    Arthritis Res Ther 8:R167. 2006
    ..In spite of the limited number of patients, our data suggest that BAFF and APRIL are differentially regulated in different autoimmune diseases and, in addition, differently affected by rituximab treatment...
  3. ncbi Serial re-challenge with influenza vaccine as a tool to study individual immune responses
    Therese Vallerskog
    Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
    J Immunol Methods 339:165-74. 2008
    ..The method also allows humoral memory and immune competence per se to be studied on a cellular level in different patient groups...
  4. ncbi HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay
    Heidi Wähämaa
    Rheumatology Unit, Department of Medicine, Karolinska Institutet CMM L8 04, Karolinska sjukhuset, Stockholm, Sweden
    J Leukoc Biol 81:129-36. 2007
    ..We believe the ELISPOT method provides a novel tool to study pathways promoting or inhibiting HMGB1 secretion...